POPular GUILTY PILOT: Genotype-guided Clopidogrel Monotherapy

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 200 participants.

Also called NCT05926271

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05926271
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Netherlands (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05926271. Allocation not applicable; no masking; primary purpose treatment. Start 2023-07-15 (actual); primary completion 2026-06-15 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
POPular GUILTY PILOT: Genotype-guided Clopidogrel Monotherapy
Acronym
POPular GUILTY
Condition
Acute Coronary Syndrome
Condition
CYP2C19 Polymorphism
Intervention (Drug)
Clopidogrel
Lead sponsor
St. Antonius Hospital (class: other)

Record details

Record id
cardio:ct-nct05926271
Content hash
07f5f09645eafe0770e407eb0d469efbf5043d43b8d14d6d958ebd7c4d2482d6